August 29, 2016 10:13 AM EDT
News Briefing

Pro­to­cols: Leap re­verse merges with a fail­ing Macro­cure; Fer­ring bags rights to PhI­II sci­at­i­ca drug

John Carroll

Editor & Founder

Leap Ther­a­peu­tics is re­verse merg­ing its way on­to the stock ex­change. Leap signed a deal with Macro­cure to merge op­er­a­tions, with Health­Care Ven­tures in­vest­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times